Pharvaris (PHVS) Cash from Operations (2020 - 2026)
Pharvaris (PHVS) posted Cash from Operations of 57092530.86 for Q1 2026, down 29.23% on a QoQ basis from 44178661.81 in Q4 2025, and down 41.08% year-over-year from 96901332.11 in Q1 2025.
Pharvaris (PHVS) Cash from Operations (2020 - 2026) Analysis & Trends
Pharvaris' Cash from Operations history runs 7 years deep, the most recent figure standing at 57092530.86 for Q1 2026.
- Quarterly Cash from Operations fell 41.08% year-over-year to 57092530.86 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 171061398.25 (down 18.66% YoY) and the FY2025 annual result came in at 154867325.53, down 19.11% from the prior year.
- Cash from Operations was 57092530.86 for Q1 2026 at Pharvaris, down from 44178661.81 in the prior quarter.
- Across five years, Cash from Operations topped out at 49734863933114.66 in Q3 2023 and bottomed at 49750167596353.37 in Q2 2023.
- A 5-year average of 927569736.49 and a median of 29811657.54 in 2024 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 324922255.76% in 2023, while the deepest fall reached 340632884.32% in 2023.
- Pharvaris' Cash from Operations stood at 20826281.92 in 2022, then decreased by 23.0% to 25616942.47 in 2023, then plunged by 45.81% to 37351343.8 in 2024, then decreased by 18.28% to 44178661.81 in 2025, then decreased by 29.23% to 57092530.86 in 2026.
- Business Quant data shows PHVS's Cash from Operations at 57092530.86 in Q1 2026, 44178661.81 in Q4 2025, and 35853648.89 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | -57.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.09 Mn |
| Mar 31, 2026 | -57.09 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Sep 30, 2025 | -35.85 Mn |
| Sep 30, 2025 | -35.85 Mn |
| Jun 30, 2025 | -33.94 Mn |
| Jun 30, 2025 | -33.94 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -37.35 Mn |
| Dec 31, 2024 | -37.35 Mn |
| Sep 30, 2024 | -36.53 Mn |
| Sep 30, 2024 | -36.53 Mn |
| Jun 30, 2024 | -29.81 Mn |
| Jun 30, 2024 | -29.81 Mn |
| Mar 31, 2024 | -26.32 Mn |
| Mar 31, 2024 | -26.32 Mn |
| Dec 31, 2023 | -25.62 Mn |
| Dec 31, 2023 | -25.62 Mn |